David Neustaedter, Ph.D., is a Venture Partner on the Medical Technologies team and joined the Firm in 2022. Prior to Deerfield, Dr. Neustaedter spent seven years as a Vice President, at Medtronic Ventures and, before Medtronic’s merger with Covidien, spent a further 7 years with Covidien including five years as a Vice President of Venture Capital. He has also held positions at Stryker Development, Leerink Swann/MEDACorp Strategy Consulting, Fletcher Spaght, and Braun Consulting. Dr. Neustaedter holds a B.Sc. in Cellular, Molecular, and Microbial Biology from University of Calgary, an M.B.A  from Yale University, and a Ph.D. in Molecular Biology from University of British Columbia.

Nehan Chatoor is an Analyst on the Medical Technologies team. Ms. Chatoor joined the Firm in 2021 as a Data Scientist before transitioning to her current role in 2023. Prior to Deerfield, she was a Senior Data Scientist at Collective Health, a health-tech startup, in the Business Intelligence group. Before Collective Health, she was a consultant for Oliver Wyman for nearly two years. Ms. Chatoor holds a B.A. in Economics and an M.S. in Management Science and Engineering from Stanford University.

Andrew ElBardissi, M.D., is a Partner on the Medical Technologies team and joined the Firm in 2017. Prior to Deerfield, Dr. ElBardissi was a Principal at Longitude Capital, where he focused on investments in medtech and biotechnology. Before that, he was an Associate in JPMorgan’s healthcare investment banking practice. Dr. ElBardissi received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has authored over 30 publications in leading peer-reviewed scientific journals and has presented his research at numerous medical and surgical conferences. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University.

Avi Kometz, M.D., is a Partner on the Medical Technologies team and joined the Firm in 2014. Prior to Deerfield, Dr. Kometz was a Partner at Ascent Biomedical Ventures, where he led investment efforts in biotechnology, pharmaceuticals, medical devices and healthcare information technology. Before Ascent, Dr. Kometz served as the head of corporate development at a specialty pharmaceutical company focused on pediatrics. He was also a member of the Healthcare Practice at McKinsey & Company in New York, where he worked on matters including strategy, valuation, organizational change and cost-reduction. Dr. Kometz received his medical doctorate from the University of the Witwatersrand Medical School, South Africa. He began his career as a clinician in South Africa and went on to found and build a group of clinics.

Steven Hochberg is an Operating Partner on the Medical Technologies team and joined the Firm in 2013 to work on structured transactions in Deerfield’s Private Design Funds. He has been a founder and manager of healthcare companies for more than twenty years. In addition to his role with Deerfield, since 2004, Mr. Hochberg has managed Ascent Biomedical Ventures, a venture capital firm he co-founded focused on early stage investment and development of biomedical companies. In 2022, he co-founded Triatomic Capital, a technology-focused venture capital firm. Since 2011, Mr. Hochberg has been the Chairman of the Board of Continuum Health Partners until its merger with Mount Sinai in 2013, where he is now the Vice Chairman of the Mount Sinai Health System, a non-profit healthcare integrated delivery system in New York City with over $8 billion in annual revenues. He graduated from the University of Michigan with a B.S. in Business Administration and earned his M.B.A. from Harvard Business School.

Gilan Megeed is a Principal on the Medical Technologies team. Ms. Megeed joined the Firm in 2014 as part of the Deerfield Institute, before transitioning to the Medical Technologies team in 2017. Prior to Deerfield, Ms. Megeed spent three years as an epidemiologist at Decision Resources Group, focusing primarily on rare diseases and neurological disorders. Prior to this, she was an Analyst at Children’s Hospital Boston, forecasting disease outbreaks and epidemics with the Computation Epidemiology Group. Ms. Megeed earned her undergraduate degree in Cell Biology and Neuroscience from Montana State University, Bozeman and holds an M.P.H. from Boston University.

Wenxi Chen is a Principal on the Medical Technologies team. Prior to joining the Medical Technologies team in 2018, Ms. Chen spent two years working in the Deerfield Institute, where she conducted market research across all sectors of the healthcare industry. She joined the Firm in 2015 as a Fellow. Ms. Chen holds a B.S. in Finance from The City University of New York’s Baruch College.

Dafna Yacobian is an Analyst on the Medical Technologies team. Ms. Yacobian joined the Firm in 2017 as a Fellow. She holds a B.A. in Biology from The City University of New York’s Macaulay Honors College.